Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TOP2A | P11388 | 2/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.51 |
| ▸ | MIF | P14174 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20497346 | 0.94 | MEN1 (0.50) | MEN1KMT2ATOP2ATOP2BMIF | |
| SCHEMBL1936309 | 0.86 | TOP2A (0.50) | MEN1KMT2ATOP2ATOP2BALDH1A1 | |
| SCHEMBL18232048 | 0.86 | NAAA (0.54) | MEN1KMT2ATOP2ATOP2BALDH1A1 | |
| SCHEMBL12898184 | 0.86 | NAAA (0.54) | TOP2ATOP2BALDH1A1NPC1RAB9A | |
| SCHEMBL23275293 | 0.85 | TOP2A (0.49) | TOP2ATOP2BALDH1A1NPC1RAB9A | |
| SCHEMBL13632263 | 0.85 | GAA (0.55) | MEN1KMT2ATOP2ATOP2BALDH1A1 | |
| SCHEMBL20497336 | 0.85 | KMT2A (0.51) | MEN1KMT2ATOP2ATOP2BALDH1A1 | |
| SCHEMBL16772111 | 0.85 | TOP2A (0.49) | TOP2ATOP2BALDH1A1LMNANPC1 | |
| SCHEMBL20160133 | 0.85 | TOP2A (0.49) | MEN1KMT2ATOP2ATOP2BALDH1A1 | |
| SCHEMBL12291924 | 0.85 | TOP2A (0.49) | MEN1KMT2ATOP2ATOP2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | claimed |
| EP-3655394-B1 | NOVEL ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | UNIV BERLIN TECH (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-2956437-B1 | ALBICIDIN DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | UNIV BERLIN TECH (DE) | 2023-05-10 | — | — | EP | disclosed |
| US-9416390-B2 | Electric measurement of monolayers following pro-cleave detection of presence and activity of enzymes and other target analytes | OHMX CORPORATION (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140027310-A1 | ELECTRIC MEASUREMENT OF MONOLAYERS FOLLOWING PRO-CLEAVE DETECTION OF PRESENCE AND ACTIVITY OF ENZYMES AND OTHER TARGET ANALYTES | OHMX CORPORATION | 2014-01-30 | — | — | US | disclosed |
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2386565-A2 | Compounds and methods to inhibit or augment an inflammatory response | Cambridge Enterprise Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-7989466-B2 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. | 2008-02-21 | — | — | US | disclosed |
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | disclosed |
| EP-1141011-A2 | COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | NEORX CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042071-A2 | COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CCL2, CCL11, CCL5 | MEN1 2434/4885KMT2A 4857/4885TOP2A 4744/4885 |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CCL2, CCL5, CCL11 | MEN1 4511/4885KMT2A 4863/4885TOP2A 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.